Aquestive Therapeutics, Inc. AQST Non-cash financing activities: accrued taxes on share-based compensation
Non-cash financing activities: accrued taxes on share-based compensation at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept aqst:ShareBasedCompensationAccruedTaxes.
The official record: Aquestive Therapeutics, Inc.’s 10-K, filed March 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s non-cash financing activities: accrued taxes on share-based compensation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s non-cash financing activities: accrued taxes on share-based compensation?
- Aquestive Therapeutics, Inc. (AQST) reported non-cash financing activities: accrued taxes on share-based compensation of $0 in Q4 2025.
- How has Aquestive Therapeutics, Inc.'s non-cash financing activities: accrued taxes on share-based compensation changed year-over-year?
- Aquestive Therapeutics, Inc.'s non-cash financing activities: accrued taxes on share-based compensation decreased by 100.0% year-over-year, from $62.5K to $0.
- What does non-cash financing activities: accrued taxes on share-based compensation mean?
- Tracks the non-cash accrual of tax liabilities associated with employee share-based compensation arrangements. This metric helps investors understand the tax-related obligations triggered by equity grants without impacting immediate cash reserves.